Bland KI, Copeland EM, Klimberg VS, Gradishar WJ. The breast: comprehensive management of benign and malignant diseases: Elsevier Health Sciences; 2023.

Guanghui R, Xiaoyan H, Shuyi Y, Jun C, Guobin Q (2019) An efficient or methodical review of immunotherapy against breast cancer. J Biochem Mol Toxicol 33(8):e22339

Article  PubMed  Google Scholar 

Almagro JC, Daniels-Wells TR, Perez-Tapia SM, Penichet ML (2018) Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front Immunol 8:1751

Article  PubMed  PubMed Central  Google Scholar 

Waks AG, Winer EP (2019) Breast cancer treatment: a review. JAMA 321(3):288–300

Article  CAS  PubMed  Google Scholar 

Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39(13):1485–1505

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P (2010) Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 123:701–708

Article  CAS  PubMed  Google Scholar 

Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH et al (2015) EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer. PLoS ONE 10(12):e0144535

Article  PubMed  PubMed Central  Google Scholar 

Zoratti GL, Tanabe LM, Hyland TE, Duhaime MJ, Colombo É, Leduc R et al (2016) Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget 7(36):58162

Article  PubMed  PubMed Central  Google Scholar 

Liu F, Gu LN, Shan BE, Geng CZ, Sang MX (2016) Biomarkers for EMT and MET in breast cancer: an update. Oncol Lett 12(6):4869–4876

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barzaman K, Vafaei R, Samadi M, Kazemi MH, Hosseinzadeh A, Merikhian P et al (2022) Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk. Cancer Cell Int 22(1):259

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ngwenya T. Development of recombinant immunotherapeutics for triple-negative breast cancer (TNBC). 2023.

Tokunaga Y, Takeuchi K (2020) Role of NMR in high ordered structure characterization of monoclonal antibodies. Int J Mol Sci 22(1):46

Article  PubMed  PubMed Central  Google Scholar 

Tilegenova C, Izadi S, Yin J, Huang CS, Wu J, Ellerman D, et al., editors. Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies. MAbs; 2020: Taylor & Francis.

Sawant MS, Streu CN, Wu L, Tessier PM (2020) Toward drug-like multispecific antibodies by design. Int J Mol Sci 21(20):7496

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asano T, Tanaka T, Suzuki H, Li G, Ohishi T, Kawada M et al (2022) A defucosylated anti-EpCAM monoclonal antibody (EpMab-37-mG2a-f) exerts antitumor activity in xenograft model. Antibodies 11(4):74

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evers A, Krah S, Demir D, Gaa R, Elter D, Schroeter C, et al., editors. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET. MAbs; 2024: Taylor & Francis.

Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi DA, Palma SD (2017) Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. Elsevier, Nanostructures for drug delivery, pp 807–833

Google Scholar 

Allen GM, Lim WA (2022) Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nat Rev Cancer 22(12):693–702

Article  CAS  PubMed  Google Scholar 

Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A et al (2019) MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proc Natl Acad Sci 116(15):7533–7542

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li G, Suzuki H, Tanaka T, Asano T, Yoshikawa T, Kaneko MK et al (2023) Epitope mapping of an anti-EpCAM monoclonal antibody (EpMab-37) using the alanine scanning method. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 42(1):41–47

Article  PubMed  Google Scholar 

Kufer P, Raum T. Human antibodies that bind human 17-A1/EpCAM tumor antigen. Google Patents; 2007.

Mirzaei R, Shafiee S, Vafaei R, Salehi M, Jalili N, Nazerian Z et al (2023) Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer. Int Immunopharmacol 122:110656

Article  CAS  PubMed  Google Scholar 

Leem J, Dunbar J, Georges G, Shi J, Deane CM, editors. ABodyBuilder: automated antibody structure prediction with data–driven accuracy estimation. MAbs; 2016: Taylor & Francis.

Nowakowski AB, Wobig WJ, Petering DH (2014) Native SDS-PAGE: high resolution electrophoretic separation of proteins with retention of native properties including bound metal ions. Metallomics 6(5):1068–1078

Article  CAS  PubMed  Google Scholar 

Manns JM. SDS‐polyacrylamide gel electrophoresis (SDS‐PAGE) of proteins. Current protocols in microbiology. 2011;22(1):A. 3M. 1-A. 3M. 13.

Bass JJ, Wilkinson DJ, Rankin D, Phillips BE, Szewczyk NJ, Smith K et al (2017) An overview of technical considerations for Western blotting applications to physiological research. Scand J Med Sci Sports 27(1):4–25

Article  CAS  PubMed  Google Scholar 

Mahmood T, Yang P-C (2012) Western blot: technique, theory, and trouble shooting. N Am J Med Sci 4(9):429

Article  PubMed  PubMed Central  Google Scholar 

Yang H, Karl MN, Wang W, Starich B, Tan H, Kiemen A et al (2022) Engineered bispecific antibodies targeting the interleukin-6 and-8 receptors potently inhibit cancer cell migration and tumor metastasis. Mol Ther 30(11):3430–3449

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baeuerle P, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96(3):417–423

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gunasinghe ND, Wells A, Thompson EW, Hugo HJ (2012) Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 31:469–478

Article  CAS  PubMed  Google Scholar 

Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S et al (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosom Cancer 47(12):1025–1037

Article  CAS  PubMed  Google Scholar 

Schoenfeld K, Harwardt J, Kolmar H. Better safe than sorry: dual targeting antibodies for cancer immunotherapy. Biological Chemistry. 2024.

Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y et al (2022) Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 7(1):39

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao H-P, Tong X-M, Wang M-H (2021) Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase. Drug Discovery Today 26(1):106–121

Article  CAS  PubMed  Google Scholar 

He Q, Hu H, Yang F, Song D, Zhang X, Dai X (2023) Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. Biomed Pharmacother 162:114609

Article  CAS  PubMed  Google Scholar 

Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M et al (2019) Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 154:21–31

Article  CAS  PubMed  Google Scholar 

Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O et al (2012) Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling. Nature 484(7392):110–114

Article  CAS  PubMed